Top Breaking News | More News | Featured Stories | News By Subject | Event News | Investor News | News Archive | Search News
Get Our FREE
Industry eNewsletter
email:    

Investor News

Clinical Development News
Pre-Clinical
IND
Phase I - Safety
Phase II - Safety and Efficacy
Phase III - Controlled Safety and Efficacy
BLA/NDA/ANDA
PDUFA
Approvable Letters
Approval and Marketing Clearance
Post-Approval
Discontinued
Recalls and Warnings

Deals & Dollars News
Alliances
Earnings Reports
Financial
Investor
Mergers and Acquisitions
Start-Ups

IPO News
IPO


Clinical - Phase I
Johnson & Johnson (JNJ) Pledges $200 Million To Ebola, Will Begin Testing Vaccine In January 2015 10/22/2014 5:45:21 AM
iCo Therapeutics Inc. Announces Advancement Of Oral Amphotericin B Program 10/22/2014 8:19:54 AM
Atara Biotherapeutics (ATRA) Doses First Patient In Phase 1 Clinical Study Of STM 434, An Activin Inhibitor 10/22/2014 7:15:43 AM
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/20/2014 3:28:01 AM
Athera Biotechnologies Initiates Phase I Trial With Its Fully Human Antibody PC-mAb 10/21/2014 10:54:58 AM
Cornerstone Pharmaceuticals, Inc. Initiates Phase I Clinical Trial Of CPI-613 For The Treatment Of Hodgkin's Or T-Cell Non-Hodgkin's Lymphoma 10/21/2014 10:40:45 AM
Generex Biotechnology Corporation (GNBT) Announces Publication Of Ebola Vaccine White Paper By Antigen Express, Inc. (GNBT) 10/21/2014 9:30:53 AM
Agios Pharmaceuticals (AGIO) Announces Initiation Of A Phase 1/2 Clinical Trial Of AG-221 In Patients With Advanced Solid Tumors With An IDH2 Mutation 10/21/2014 7:42:29 AM
ChemoCentryx, Inc. (CCXI)'s Orally Administered CCR9 Inhibitor, CCX507, Shown To Be Well Tolerated And Effective In CCR9 Blockade In Phase I Study 10/21/2014 7:41:23 AM
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/20/2014 3:28:01 AM
Novartis AG (NVS)'s Leukemia Drug CTL01 Clears Cancer In 90 Percent Of Patients 10/15/2014 5:27:29 PM
AgonOx’s OX40 Platform Being Utilized In MedImmune (AZN)’s Phase 1 OX40 Agonist Study 10/20/2014 9:22:39 AM
R-Tech Ueno: Announcement Of Initiation Of The Phase I Clinical Trial For The Novel VAP-1 Inhibitor RTU-1096 10/20/2014 9:27:54 AM
Milo Biotechnology's Follistatin Gene Therapy Increases Function In Becker Muscular Dystrophy Patients 10/20/2014 9:18:11 AM
Galapagos NV (GLPG.BR) Discloses Novel Target And Presents Favorable Phase 1 Data For GLPG1205 At UEG Week 10/20/2014 8:53:03 AM
1234567
//-->